Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Arte... (25 sites in the U.S. and will examine ra...)

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

Date:5/20/2009

25 sites in the U.S. and will examine rates of device- and/or procedure-related major adverse events (MAE) at nine months. MAE are currently defined as death within 30 days, myocardial infarction (MI, or heart attack) occurring during related hospitalization, target vessel revascularization (TVR) through nine months and amputation of the treated limb through nine months.

The EPIC Stent is a next-generation product that builds on Boston Scientific's long-time leadership in the peripheral interventions market. The Company's peripheral product lines feature technologies used to diagnose and treat peripheral disease, including stents, balloon catheters, sheaths, wires, peripheral embolization solutions and vena cava filters. This advanced product portfolio offers physicians a range of peripheral stent indications, including the Carotid Wallstent(R) Endoprosthesis for carotid artery disease and the Express(R) SD Stent for renal artery disease.

The EPIC Nitinol Stent System is an investigational device and is limited by applicable law to investigational use only and is not available for sale in the U.S.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
2. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
3. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
4. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
5. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
6. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
7. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
8. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
9. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
10. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
11. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent

Post Your Comments:

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Arte...(25 sites in the U.S. and will examine ra...),Health